Dec 12, 2022 | Becky Bosley
Saturday at ASH was INTENSE! Virtually taking in content from 7 a.m. until 9:30 p.m. While I’m exhausted, I’m energized at the same time. So much amazing research being done for the good of the patient with myeloma. I think the thing that struck me the most today was...
Dec 12, 2022 | Jill Zitzewitz
Not only is December ASH month, but in my family, it is also birthday month! I turned 59 a week ago, and two of my four children also have December birthdays. As a matter of fact, today my younger son turned 21, so I sent him a birthday text first thing when I woke up...
Dec 12, 2022 | Jessie Daw
For those living with smoldering multiple myeloma (SMM), many uncertainties exist. These uncertainties can be whittled down to two “million dollar” questions: (a) “Will I progress to active disease?” and (b) “Should I consider treatment, and if so, how and when?” This...
Dec 12, 2022 | Jack Aiello
Today’s oral presentations examined prognostic factors for newly diagnosed multiple myeloma patients, new drugs, and optimized treatment approaches, as well as prognostic markers. I’ll show some of the abstract results below from those sessions. We also met with...
Dec 11, 2022 | Jill Zitzewitz
The very first session I attended at this year’s American Society of Hematology (ASH) Annual Meeting was a Friday Satellite Symposium sponsored by Clinical Care Options and the International Myeloma Foundation. The symposium title, “A Conversation with the Myeloma...
Dec 11, 2022 | Linda Huguelet
On Saturday, our team had the distinct privilege to attend the International Myeloma Working Group (IMWG) meeting. This organization includes over 280 myeloma specialists and researchers from all over the world who share the same goal of advancing myeloma research...
